Statural growth to age ≥20 years was studied in 10 boys with glomerulonephritis who received alternate-day prednisone (mean 1.2 mg/kg) for at least 2 consecutive years during pubertal age. Peak growth velocity was delayed after age 15 years in six patients and it was less than 7 cm/year in five. However, after age 16, growth velocity was significantly (p 0.02) higher than expected and allowed patients to ultimately reach their genetic height potential.
Get full access to this article
View all access options for this article.
References
1.
1. Polito C, Oporto MR, Totino SF, eat al. Normal growth of nephrotic children during long-term alternate-day prednisone therapy. Acta Paediatr Scand. 1986;75:245-250.
2.
2. Hyams JS, Carey DE. Corticosteroids and growth. J Pediatr.1988;113:249-254.
3.
3. Rees L, Greene SA, Adlard P, et al. Growth and endocrine function in steroid-sensitive nephrotic syndrome.Arch Dis Child. 1988;63:484-490.
4.
4. Trompeter RS, Lloyd BW, Hicks J, et al. Long-term outcome for children with minimal change nephrotic syndrome. Lancet. 1985;i:368-370.
5.
5. Foote KD, BroklebankJ, Meadow SR. Height attainment in children with steroid-responsive nephrotic syndrome. Lancet. 1985;ii:917-919.
6.
6. Polito C, Di Toro R.Delayed pubertal growth spurt in glomerulopathic boys receiving alternate-day prednisone. Child Nephrol Urol. 1992;12:202-207.
7.
7. Tanner JM. Foetus into Man: Physical Growth from Conception to Maturity. London: Open Books; 1978.
8.
8. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity and stage of puberty. Arch Dis Child. 1976;51:170-179.
9.
9. Tanner JM, Whitehouse RH, Marshall WA, et al. Assessment of skeletal maturity and prediction of adult height (TW2 method). London: Academic Press; 1975.
10.
10. Broyer M.Croissance et nephropathies. In: Royer P, Habib R, Mathieu H, Broyer M, eds. Nephrologie Pediatrique. Paris: Flammarion; 1983:443-451.
11.
11. Polito C, La Manna A, Olivieri AN, Di Toro R.Proteinuria and statural growth. Child Nephrol Urol. 1989;9:286-289.
12.
12. Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia: effect of 25-hydroxyvitamin D administration. J Clin Invest. 1979; 64:655-665.
13.
13. Dykman TR, Haralson KM, Gluck OS, et al. Effect of oral 1,25-hydroxyvitanin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthyritis Rheum. 1984;27:1336-1343.
14.
14. Chesney RW, Mazess RB, Rose P, Jax DK. Effect of prednisone on growth and bone mineral content in childhood glomerular disease. Am J Dis Child. 1978;132:768-772.
15.
15. Polito C, La Manna A, Todisco N, et al. Bone mineral content in nephrotic children on long-term, alternate-day prednisone therapy. Clin Pediatr. 1995; 34:234-236.
16.
16. Blodgett FM, Burgen L, lezzoni D, et al. Effect of prolonged cortisol therapy on the statural growth, skeletal maturation and metabolic status of children. NEnglJMed. 1956;254:636-641.
17.
17. Morris HG. Growth and skeletal maturation in asthmatic children: effect of corticosteroid treatment. Pediatr Res. 1975;9:579-583.
18.
18. Kerrebjin KF, De Kroon JPM. Effect on height of corticosteroid therapy in asthmatic children. Arch Dis Child. 1968;43:556-561.
